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INTRODUCTION 
Patients with liver cirrhosis have hyperdynamic circulation, characterized 
by increased cardiac output, decreased peripheral vascular resistance and arterial 
hypotension.  Transcranial Doppler (TCD) allows observation of the velocity waveform 
in the major cerebral blood vessels.1 Some studies with TCD have shown that the mean 
cerebral blood velocity, an indicator of cerebral blood flow, is decreased or unchanged in 
patients with chronic liver disease. Dillon et al 2 reported that the mean cerebral blood 
velocity is decreased in advanced cirrhotic patients without encephalopathy. Lagi et al 3 
showed no difference in the mean cerebral blood velocity between cirrhotic patients with 
ascites and healthy controls. Guevera et al 4 measured the cerebral resistive index instead 
of cerebral blood velocity in cirrhotics and demonstrated that the resistive index is higher 
in cirrhotics with ascites than in healthy controls. Pulsatility and resistive indices are 
widely accepted as an indicator of vascular resistance.5 These parameters are more 
accurate than measurement of cerebral blood flow velocity.  
Hepatic (portal-systemic) encephalopathy is a serious complication of 
chronic liver disease and is broadly defined as an alteration in mental status and cognitive 
function occurring in the presence of liver failure. Gut-derived neurotoxins that are not 
removed by the liver because of vascular shunting and decreased hepatic mass cause the 
symptoms that we know of as hepatic encephalopathy. Ammonia levels are typically 
elevated in patients with hepatic encephalopathy, but the correlation between severity of 
liver disease and height of ammonia levels is often poor. Other compounds and 
metabolites that may contribute to the development of encephalopathy include certain 
false neurotransmitters and mercaptans.  
Proposed mechanisms for pathogenesis of hepatic encephalopathy 
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1. Accumulation of toxins (Ammonia, Mercaptans) 
2. Enhanced GABAergic neurotransmission 
3. Accumulation of false neurotransmitters  
Evidence for reproducible alterations in soluble guanylate cyclase, nitric oxide (NO), 
and related pathways also has been published.6 It is possible that alteration in cerebral 
blood flow could contribute to pathogenesis of encephalopathy. 
 This study was done to evaluate the cerebral hemodynamic parameters using TCD 
in cirrhotic patients with and without encephalopathy and compared then with healthy 
controls. 
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AIM OF THE STUDY 
The aim of this study is to assess the resistive and pulsatility indices which are 
indicators of cerebral vascular resistance in cirrhotic patients with hepatic encephalopathy 
using transcranial Doppler ultrasonography.  
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REVIEW OF LITERATURE 
Hepatic encephalopathy (HE), or portosystemic encephalopathy, is characterised 
by reversible decrease in neurologic function caused by liver disease.7 This complication 
can develop in about 30-45% of cirrhotics at any point of time.8 Two major determinants 
for this syndrome are liver parenchymal dysfunction and portosystemic shunt. 
Spontaneous shunts are more prevalent inpatients with hepatic encephalopathy as 
compared to patients with other forms of decompensation like ascites.9 Similarly, 
cognitive impairment is more common in advanced liver disease (Child C) than in Child 
A cirrhotics.10 Spectrum of HE ranges from pre-symptomatic minimal HE to symptomatic 
over HE. Decompensation of chronic liver disease in the form of HE confers a worse 
prognosis. A retrospective analysis showed survival probability of 42% at one year and 
23% at 3 years after presenting with an encephalopathy episode.11 
The precise pathogenic mechanisms for HE are not fully defined. Decades of 
experience with animal models, including dogs with a surgically created Eck fistula (end-
to-side portocaval shunt), 12 have identified the essential pathophysiologic elements. In 
the setting of portosystemic shunting, by which portal blood is diverted away from the 
liver and into the vena cava, ingestion of a protein meal is associated with the onset of 
encephalopathy and progression to coma and death. Although the precise mechanisms are 
not established, these findings suggest that absorption of nitrogenous by-products of 
proteins from the colon into the portal circulation plays a key role. 
This pathophysiologic model of hepatic encephalopathy is simplistic in some 
ways and does not account for other potentially important parameters, such as changes in 
central neurotransmitters and the blood-brain barrier, 13 but the model fits well with 
clinical experience and makes no assumptions about the precise identity of the toxin(s) 
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involved. For example, even though creation of a portacaval shunt is highly effective for 
treatment of bleeding associated with portal hypertension, the clinical consequence is 
increased shunting and an increase in the frequency and severity of encephalopathy. 14 
Therefore, recognition of these key features - portosystemic shunting and defective 
hepatic clearance of nitrogenous metabolites—continues to form the basis of standard 
treatments for HE. 
Is ammonia the toxin responsible for HE? Yes, but not the only one, and the 
mechanisms whereby ammonia produces neuropsychiatric abnormalities are not fully 
defined. 15 In most relevant clinical series, elevated blood ammonia levels are detected in 
60% to 80% of patients with cirrhosis and encephalopathy, and therapy aimed at 
decreasing the concentration of ammonia results in resolution of encephalopathy. 16 It is 
clear, however, that multiple metabolic abnormalities coexist, including changes in the 
profile of circulating amino acids, mercaptans, and central nervous system levels of 
dopamine and other neurotransmitters. 17 These alterations are present to a variable extent 
in different clinical scenarios of HE and probably work in a complementary manner to 
modify neurologic function in cirrhosis. Even if ammonia is not the only cause, or even 
the predominant cause, of HE, it is a clinically useful marker of the production of enteric 
toxins from nitrogenous substrates.  
Detailed reviews of the pathogenesis and molecular mechanisms of HE have been 
published. 18 The focus on the role of ammonia and on the potential role of inhibitory 
neurotransmission through γ-aminobutyric acid (GABA) receptors in the central nervous 
system is based on the importance of ammonia as a guide to therapy and the emerging 
support for the GABA receptor complex as a target for newer therapies. Mechanisms 
involving changes in central neurotransmitters and circulating amino acids also are 
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relevant, but their therapeutic implications are not as well defined. It is notable, for 
example, that in an animal model of HE, exploratory studies using micro-array 
technology to detect messenger RNA (mRNA) levels have demonstrated a two-fold 
increase in 16 mRNA transcripts and a two-fold decrease in 15 transcripts. 23 Some of 
these transcripts are derived from genes involved in neurotransmitter receptors, 
transporters, signal transduction, and the cellular response to oxidative stress. Evidence 
for reproducible alterations in soluble guanylate cyclase, nitric oxide (NO), and related 
pathways also has been published. 20 These multiple changes and the lack of unanimity 
regarding which one is primary underscore the need for continued efforts to improve our 
understanding of this important complication of liver failure. 
Ammonia hypothesis: 
Ammonia is a key intermediate in nitrogen and protein metabolism, and the 
dynamics of ammonia handling in humans are well defined. 21 The gastrointestinal tract is 
the primary site of ammonia production. Nitrogenous compounds in the colon, which 
include ingested proteins and secreted urea, are degraded by bacteria with liberation of 
ammonia, which is then absorbed into the portal circulation, where concentrations are 5- 
to 10-fold greater than in mixed venous blood. 22 The first-pass extraction of ammonia by 
the liver is high, resulting in clearance of ammonia from the portal system and prevention 
of its entry into the systemic circulation. Within hepatocytes, ammonia is converted 
rapidly by a series of enzymatic reactions to nontoxic glutamine and is synthesized in 
separate reactions into urea for secretion by the kidneys. Abnormalities in urea cycle 
enzymes occur in congenital syndromes, but enzyme deficiencies are not the major 
concern in most patients with cirrhosis, in whom ammonia bypasses the liver as a result 
of portosystemic shunting. 
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In addition to their role in urea transport, the kidneys are a site of ammonia 
generation and actively secrete ammonia into the urine. Indeed, a net increase in the 
concentration of ammonia is observed in the renal veins as compared with the renal 
arteries, and the concentration of ammonia in the renal veins is increased by hypokalemia 
and use of diuretics. 23 Clinical studies support a role for hypokalemia in precipitating HE 
through an effect on renal ammoniagenesis. 28 
Following bolus injection of radiolabeled ammonia, the liver, bladder, and brain 
show appreciable uptake. In encephalopathy, arterial ammonia levels increase and the rate 
of accumulation of ammonia in the brain also increases from 32 ± 3 μmol/min to 53 ± 7 
μmol/min. Because muscle is an important site of ammonia clearance, the muscle atrophy 
seen in advanced cirrhosis may contribute to the increase in the uptake of ammonia by the 
brain. 
Although the implications of these observations regarding ammonia metabolism, 
portosystemic shunting, and the pathogenesis of HE are not fully defined, in aggregate the 
observations indicate a clear relationship between HE and abnormal ammonia handling. 
Difficulties in the measurement and interpretation of blood ammonia levels 
include 
 (1) Substantial variations in venous as compared with arterial ammonia levels;  
(2) Exercise-induced release of ammonia from skeletal muscle;  
(3) A poor correlation between the absolute value of the blood ammonia level and 
the degree of encephalopathy; and  
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(4) Differences in the time course between the rise in blood ammonia levels and 
the onset of symptoms of encephalopathy. 29 Despite these limitations, measures to lower 
arterial ammonia levels remain a cornerstone of the management of hepatic coma. 30  
Patients with cirrhosis are subject to changes in systemic fluid and electrolyte 
balance by virtue of the sodium and water retention that accompanies cirrhosis and the 
frequent use of potent diuretics. Because encephalopathy commonly is precipitated by 
metabolic events, 32 it is instructive to consider how abnormalities in acid-base and 
electrolyte balance influence ammonia metabolism, with the assumption that increases in 
blood ammonia levels increase the severity of encephalopathy. The effects of uraemia are 
predictable, because urea diffuses into the colon, where it is metabolized to liberate 
ammonia after bacterial degradation. The effects of hypokalemia and alkalosis are more 
subtle. Hypokalemia frequently develops in cirrhotic patients as a consequence of 
diuretic-induced urinary losses, diarrhoea, vomiting, and nutritional deficiencies. First, 
hypokalemia increases ammonia production by the kidney. Second, hypokalemia and 
alkalosis favour cellular uptake of ammonia. Because most of the body's K+ stores are 
found in the intracellular space, lowering K+ concentrations in the extracellular fluid 
stimulates efflux of K+ out of cells to restore extracellular concentrations. Cells 
compensate for the loss of K+ by a net uptake of Na+ and H+ ions to maintain 
electroneutrality, thereby leading to relative alkalinization of the extracellular space and 
acidification of the intracellular space. Because ammonia (NH3) and ammonium ion 
(NH4+) exist in equilibrium, the extracellular alkalosis increases the portion of membrane-
permeable NH3, whereas the intracellular acidosis serves to trap NH4+ within the cell. 
Therefore, the net effect of hypokalemia is a shift of ammonia into neurons or other cells, 
where it exerts its toxic effects. Consequently, normalizing hypokalemia is therapeutic. 
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Despite the strong evidence that implicates ammonia as an important contributor 
to HE, the precise cellular mechanisms involved remain elusive. Several potential 
mechanisms of ammonia-induced neuronal dysfunction have been described. Ammonia 
has been reported to decrease the concentration of glycogen in cultured astrocytes, 29 
impair glial-neuronal communication, 30 and interfere with synaptic transmission. Over 
longer periods, sustained elevation of ammonia levels induces pathologic changes in 
perineural astrocytes. Because glycogen stores in astrocytes represent an important 
energy reserve for the brain, disruption of glial-neuronal signaling may play a role on the 
pathogenesis of HE. 31Observations in animal models of HE and hyperammonemia 
support these general conclusions, although the multiple effects of ammonia and its 
metabolites have not been fully resolved. In addition, ammonia modulates cell signaling 
through effects on glutamate and GABA signaling, and alterations in ammonia 
metabolism and GABA signaling are thus related. 
γ-Aminobutyric Acid Hypothesis:  
Ammonia causes some of the symptoms and signs of HE only after it is 
metabolized by glutamine synthetase in the brain. In an animal model of HE, portacaval 
shunting has been shown to lead to increases in plasma and brain ammonia 
concentrations, as well as increases in brain glutamine and tryptophan levels as a result of 
the action of glutamine synthetase. 32 Inhibition of glutamine synthetase results in 
normalization of brain glutamine concentrations and normalization of glucose 
consumption, supporting a role for glutamine synthesis in the development of cerebral 
metabolic abnormalities in hyperammonemic states. Therefore, ammonia alone does not 
explain the central nervous system abnormalities in HE. 
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Studies in humans and animal models have implicated the GABA receptor 
complex as a key contributor to neuronal inhibition in HE.33   (Fig 1a & 1b) The GABA 
receptor complex is localized to postsynaptic membranes and constitutes the principal 
inhibitory network in the central nervous system. The complex consists of (1) a GABA-
binding site that faces the extracellular surface; (2) a Cl--selective pore that opens in 
response to GABA binding to permit influx of Cl- and produce membrane 
hyperpolarization; and (3) closely associated barbiturate and benzodiazepine receptor 
sites that potentiate the effects of GABA. The endogenous ligands for the benzodiazepine 
receptor have not been clearly identified. 
 
Fig 1a γ-Aminobutyric acid (GABA) receptor–chloride (Cl-) channel complex in the postsynaptic membrane 
Theoretically, increases in GABAergic transmission could result from increased 
availability of extracellular GABA or benzodiazepine receptor ligands. The liver contains 
high concentrations of GABA and GABA trans-aminase. 38 Liver injury disrupts GABA 
homeostatic mechanisms and may thereby contribute to the pathogenesis of HE. In 
addition, ammonia combines with α-ketoglutarate in the central nervous system to form  
 20
 
Fig 1b Major steps in glutamatergic neurotransmission. Glutamate released from the 
presynaptic neuron is taken up into the perineuronal astrocyte via the glutamate 
transporter-1 (GLT-1) and the glutamate—aspartate transporter (GLAST) or the neuronal 
excitatory amino acid carrier-1 (EAAC1). Glutamate receptors are expressed on neurons 
(NMDA, AMPA, kainate [KA] subtypes) and astrocytes (AMPA, KA subtypes). Ammonia 
(NH3) removal by glutamine synthetase (GS) occurs only in the astrocyte. In acute liver 
failure, decreased expression of GLT-1 and concomitant increases of extracellular 
glutamate may signify impaired neuron—astrocyte trafficking. GLNase, glutaminase; 
CSF, cerebrospinal fluid. 
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glutamate, which, in turn, is amidated to produce GABA. Therefore, increased 
production of GABA would be expected to correlate with ammonia levels. 
The evidence for the role of endogenous benzodiazepine receptor ligands in 
increasing GABAergic transmission, however, is stronger 35 In the absence of known 
ligands, putative benzodiazepine receptor agonists are identified by their competitive 
inhibition of flumazenil (a benzodiazepine receptor antagonist) binding. In both animal 
and human models, HE is associated with an increase in levels of benzodiazepine receptor 
ligands. Similarly, benzodiazepine-like activity is increased in cerebrospinal fluid, blood, 
and urine in humans with HE. Several additional points merit emphasis. First, gut bacteria 
provide precursors of benzodiazepine receptor ligands, just as they produce ammonia. 
Impairment of hepatic clearance of such ligands in patients with cirrhosis parallels the 
reduced clearance of ammonia, and treatment to lower ammonia levels would be expected 
to have similar effects on levels of benzodiazepine receptor ligands. Second, the 
concentration of these ligands correlates roughly with the stage of HE. Finally, HE is 
ameliorated in some patients by flumazenil or its structurally related analogs Ro 15-3505 
and Ro 15-4513. 
The efficacy of flumazenil in the treatment of HE has been studied in several 
clinical trials. In general, intravenous infusion of flumazenil (0.4 to 1 mg) results in 
modest but rapid improvement in the EEG and a more delayed improvement in the 
patient's mental status. 36 Some of the responders in these trials had received 
pharmaceutical benzodiazepines. Other studies, including blinded cross-over trials, have 
failed to identify a beneficial effect of flumazenil. 37 The reasons for the different results 
are not clear. In a literature review encompassing 13 trials and 805 patients, short-term 
improvement was detectable following treatment with flumazenil, but no appreciable 
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change in rates of recovery or mortality was observed. Therefore, most beneficial 
responses usually are incomplete, without full recovery to normal mental status, and are 
short-lived, perhaps because flumazenil-like drugs are incomplete benzodiazepine 
receptor blockers, or, more likely, other factors such as ammonia, mercaptans, and amino 
acids also contribute to HE.  
These studies support a role for benzodiazepine receptor ligands in the 
pathogenesis of HE and suggest that flumazenil or other benzodiazepine receptor 
antagonists may be useful in the treatment of HE. Clearly, these agents are of benefit in 
reversing the effects of exogenous benzodiazepines, may provide useful prognostic 
information, and may aid in the differential diagnosis of coma. Although the findings in 
animal models are not necessarily generalizable to all forms of liver injury, the 
implications are intriguing: Encephalopathy may be caused in part by an increase in 
inhibitory neurotransmitter tone in the central nervous system. It merits emphasis that 
ammonia potentiates GABAergic transmission, thereby supporting the concept that the 
ammonia hypothesis and the GABA hypothesis are functionally related. 
Nomenclature of hepatic encephalopathy: 
The Working Party at the XI World Congress of Gastroenterology 1998 proposed a 
nomenclature that defines HE with respect to  
1. The nature of hepatic abnormality 
2. Duration and characteristics of neurologic manifestations. 38  
The nomenclature broadly categorises HE by the nature of hepatic abnormality into 3 
types 
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1. Type A: HE associated with acute liver failure 
2. Type B: HE associated with portosystemic bypass and no intrinsic hepatocellular 
disease 
3. Type C: HE associated with cirrhosis and portal hypertension and/or 
portosystemic shunts. 
TYPE A HEPATIC ENCEPHALOPATHY 
It is recognised in the presence of acute liver injury which often progresses 
rapidly. Within hours or days, patient may deteriorate to coma. It is often associated 
with seizures, decerebrate rigidity and frequently, death. 39 This is associated with a 
high mortality rate and death is usually due to cerebral herniation and hypoxia 
characterised by increased intracranial pressure. Cerebral oedema is partly attributed 
to swelling of astrocytes. 40 The most common etiology includes acetaminophen 
overdose and viral hepatitis. 
TYPE B HEPATIC ENCEPHALOPATHY 
In type B HE, toxins bypass the liver and enter central nervous system due to the 
development of portosystemic shunts which connects the portal venous system 
supplying blood to the liver with systemic circulation. There is no associated intrinsic 
liver disease. Portosystemic shunts can be congenital, artificial or spontaneous. Type 
B HE is rare. 
TYPE C HEPATIC ENCEPHALOPAHTY 
It is usually associated with cirrhosis and portal hypertension with or without 
portosystemic shunt. 
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 Type B and C HE are divided into categories of episodic, persistent and minimal, 
based on the duration and characteristics of neurological manifestations. 
 The Working Party recommended that the term ‘subclinical’ be replaced with 
‘minimal’ because of potential misinterpretation that could arise from use of former 
term. It also helped to avoid medical errors induced by a name that could implicate 
that the condition is below the threshold of significance. 
WEST HAVEN CRITERIA FOR GRADING HEPATIC ENCEPHALOPATHY 41 
GRADE 0: 
1. lack of detectable changes in personality or behaviour 
2. no asterixis 
GRADE 1 
1. Trivial lack of awareness, shortened attention span, sleep disturbance and altered 
mood 
2. asterixis may be present 
GRADE 2 
1. lethargy, disorientation to time, amnesia to recent events, impaired simple 
computations, inappropriate behaviour, slurred speech 
2. asterixis is present 
GRADE 3 
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1. Somnolence, confusion, disorientation to place, bizarre behaviour, clonus, 
nystagmus and positive Babinski sign. 
2. Asterixis is usually absent. 
GRADE 4 
1. Coma, lack of verbal eye and oral response 
It is characterized by subtle and sometimes intermittent changes in memory, 
personality, concentration, and reaction times. 42. Early changes are subclinical - termed 
minimal hepatic encephalopathy (MHE)—most often recognized only in retrospect. MHE 
is clinically significant because studies of compensated cirrhotic patients without clinical 
evidence of HE indicate that more than one half perform abnormally on number 
connection tests or auditory-evoked responses, and more than one half may be unfit to 
drive an automobile, as assessed by a battery of psychometric tests. 43 
When encephalopathy progresses, the neurologic abnormalities become more 
apparent and commonly are graded on a numerical scale that reflects increasing degrees 
of neurologic dysfunction. Stage 1 encephalopathy is characterised by involvement of 
higher cortical functions, with decreases in attention span, changes in personality, 
irritability, and impaired computational and construction skills. There is also a change in 
the sleep pattern with wakefulness at night and drowsiness during the day. The EEG 
tracing may show subtle slowing of the dominant frequency.  
Progression to stage 2 encephalopathy is characterized by more drowsiness and 
lethargy, and by the appearance of movement disorders that reflect increasing 
involvement of the descending reticular system or other neurologic structures. These 
movement disorders include tremors, incoordination, and asterixis. 44 In cooperative 
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patients, asterixis is commonly evaluated by asking the patient to hold the arms extended 
with the wrists dorsiflexed; an abrupt loss of flexor tone and a characteristic wristdrop 
occur in a periodic manner every 2 to 3 seconds. Alternatively, the periodic relaxations 
become apparent when the examiner grips the patient's hand and holds the wrist lightly in 
a dorsiflexed position. In a patient with mental confusion, drowsiness, and personality 
changes, the presence of asterixis is highly suggestive of underlying hepatic 
encephalopathy. An EEG performed in stage 2 usually shows slower rhythms and the 
appearance of triphasic waves in the frontal regions. 
Progression to stage 3, defined as increasing obtundation in a still arousable 
patient, or to stage 4, in which the patient is comatose, reflects either severe bilateral 
cortical dysfunction or involvement of the brainstem and reticular activating system. 
Asterixis may be lost, and hyperreflexia and muscle rigidity become apparent. The EEG 
shows severe slowing, with frequencies in the theta and delta ranges. Even though the 
clinical features may be fully reversible with treatment (see later), encephalopathy of this 
degree generally is a manifestation of advanced liver disease and is associated with a poor 
long-term prognosis 
Hepatic encephalopathy manifests as a spectrum of neurologic abnormalities, but 
each of the individual principal clinical features is nonspecific. Subtle impairments of 
memory, consciousness, and personality are easily overlooked if the underlying liver 
disease is not recognized. Alternatively, even if well-defined periods of encephalopathy 
have been documented, it may be difficult to assess whether recovery has been complete. 
By contrast, the clinical features of advanced encephalopathy and asterixis in a patient 
with known cirrhosis and portal hypertension are quite characteristic, and the combination 
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of asterixis, hyperammonemia, and other clinical features permits confident recognition 
of portosystemic encephalopathy. 
The recognition of MHE is of particular importance in view of the prevalence of 
cirrhosis. In the absence of characteristic features, subtle abnormalities of 
neuropsychiatric function generally are assessed by more specialized neuropsychiatric 
tests such as the trail-making test, block design and digit symbol tests, and visual reaction 
times. 45   In addition, some evidence supports the use of brainstem auditory-evoked 
responses and somatosensory-evoked responses for the diagnosis of HE. 46 Some of these 
specialized tests are not readily performed in the clinical setting. Therefore, outside of the 
research setting, a high index of suspicion in patients at risk of HE, such as those with a 
recent surgical or transjugular portosystemic shunt, 47 and a beneficial response to a 
therapeutic trial are clinically more useful diagnostic approaches. 
Special attention has been paid to the cerebral functional defects of latent or 
subclinical HE with regard to the patient's fitness to drive and quality of life. Driving 
requires complex response and spatial recognition skills, and in a series of cirrhotic 
patients without clinical signs of portosystemic encephalopathy, psychometric testing 
indicated that 60% were unfit to drive and an additional 25% had questionable driving 
skills. Some, but not all, studies have confirmed a reasonably high frequency of 
subclinical encephalopathy in patients with cirrhosis, but no consensus has been reached 
on whether the ability to drive is significantly impaired in the absence of major 
abnormalities on neuropsychiatric testing. 48 Therefore, decisions regarding driving 
should be made on a case-by-case basis, with no clear support to strictly prohibit driving 
in patients with compensated cirrhosis and no overt evidence of encephalopathy. 
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Administration of lactulose does seem to be beneficial in improving psychometric 
performance.  
Progression to clinically apparent HE is commonly associated with two modes of 
presentation. Encephalopathy may be acute in onset, with rapid deterioration of mental 
function and coma in the absence of previous symptomatology, or chronic and relapsing, 
as usually occurs in patients with more pronounced portal hypertension. In either case, 
HE typically is reversible, and a precipitating cause for the deterioration usually can be 
identified and corrected. The relative contributions of different precipitating factors were 
analyzed by Fessel and Conn in 100 patients requiring hospitalization and are illustrated 
in the figure below.  Many of these precipitating factors are readily understood on the 
basis of their effects on ammonia. An increase in nitrogenous substances as a result of 
azotemia and gastrointestinal hemorrhage together accounted for almost one half of the 
admissions. Medications also figured prominently, and causative mechanisms for the 
precipitation of coma were either direct, from increased sensitivity to tranquilizers and 
sedatives, or indirect, through hypokalemia, dehydration, and alkalosis associated with 
diuretic use. Identification and correction of these causes constitute the cornerstone of 
effective therapy, and in very few patients with chronic cirrhosis is encephalopathy the 
result of an irreversible loss of hepatocyte mass and synthetic capacity.  
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Table 1 COMMON CLINICAL FACTORS THAT MAY PRECIPITATE HEPATIC 
ENCEPHALOPATHY IN PATIENTS WITH CIRRHOSIS 
 
 
Fig 2 Clinical causes of hepatic encephalopathy. GI, gastrointestinal.  (From 
Fessel JM, Conn HO: An analysis of the causes and prevention of hepatic coma. 
Gastroenterology 62:191, 1972.) 
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Blood ammonia levels may be measured when hepatic encephalopathy is 
suspected, both for diagnostic purposes and as a general guide to treatment. Normal 
ammonia values do not exclude the diagnosis and should not delay initiation of ammonia-
lowering therapy. Measurable differences exist between arterial and venous levels of 
ammonia. In practice, venous levels are measured most often for convenience and 
because no evidence is available to suggest that the accuracy of measurement or outcome 
of the patient depends on the source of the blood sample. Approximately one fourth of 
patients will have non-nitrogenous precipitants of encephalopathy, such as adverse 
reactions to sedatives and fluid and electrolyte imbalances. In view of the potential 
involvement of the GABA receptor complex and the abnormalities in multiple other 
signalling pathways in HE, it is not surprising that patients with normal ammonia values 
respond to treatment in a manner similar to those with elevated ammonia levels. 
Measurement of glutamine levels in the cerebrospinal fluid and an EEG can provide 
confirmation of the clinical impression of HE but are neither sensitive nor specific. 
The clinical stages of HE provide a general index of severity in the acute setting 
but are not sufficiently quantitative to assess subtle changes in clinical performance. 
Consequently, the need remains for a reliable, reproducible test that can be easily 
administered. The trail-making test provides a semi quantitative measure of 
encephalopathy. In this test, the subject connects 25 consecutively numbered circles, and 
the number of seconds required to complete the task is recorded 49 An alternative figure-
making test also has been introduced and validated for patients who cannot recognize 
numbers, and detects subclinical encephalopathy in 48% of subjects. 50 None of these 
measures alone is entirely satisfactory, and they are best utilized when administered 
serially to assess changes over time. The overall assessment provided by the 
Portosystemic Encephalopathy Index introduced by Conn in the 1970s and based on an 
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arbitrary measure of the degree of abnormality of five factors—clinical assessment of 
mental state, trailmaking time, EEG, asterixis, and arterial ammonia—is still unsurpassed 
as a clinical research tool. Although complex, the Index emphasizes the need for taking 
multiple parameters into account in the overall assessment and diagnosis of HE. 
In the near future, the diagnosis of HE is likely to include cerebral imaging studies 
as well. Currently, computed tomography (CT) and magnetic resonance imaging (MRI) 
are used to exclude structural causes of altered mental status such as intracerebral 
bleeding. However, MRI and 1H spectroscopy of the brain of patients with cirrhosis 
detect abnormalities in brain metabolites that correlate with encephalopathy and are 
completely reversed 3 to 7 months after liver transplantation. 51 The overall sensitivity of 
these and other techniques is not yet established, but they offer promise for real-time 
imaging of encephalopathy-specific brain metabolic changes in the future. 
The principles involved in management of HE are straightforward: identify and 
correct the precipitating cause(s), initiate ammonia-lowering therapy, and minimize the 
potential medical complications of cirrhosis and depressed consciousness. Among these, 
careful scrutiny for and correction of the underlying cause of the deterioration, such as 
bleeding, tranquilizers, electrolyte abnormalities, or azotemia, is the most important. 
These basic steps are relatively easy and effective, with excellent recovery to basal 
function in most patients when comorbid factors are absent. 
Correction of the precipitating factor for encephalopathy depends on a careful 
review of potential contributors, many of which, such as gastrointestinal bleeding, 
dehydration, hypokalemia, and azotemia, are readily apparent from the initial physical 
examination and basic laboratory studies. Particular attention should be paid to the 
possibility of gastrointestinal bleeding because of the high risk of bleeding in the setting 
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of portal hypertension and the need for specific therapeutic intervention. Catabolism of 
blood in the intestine liberates ammonia and presumably benzodiazepine receptor ligands 
and other mediators and is a classic cause of nitrogenous encephalopathy. 
Action should be taken as soon as potential precipitating factors are identified. If 
azotemia is the cause, rehydration with concomitant attention to other pre-renal factors is 
indicated. If bleeding is the precipitant, it must be controlled. Medications should be 
reviewed in detail, with specific attention to tranquilizers and sedatives and to the adverse 
effects of diuretics. Any potentially contributing medicines should be discontinued. 
Moreover, general measures to correct and maintain serum glucose levels, oxygenation, 
and acid-base balance are essential. 
The second step in treatment involves measures directed at lowering elevated 
blood ammonia levels. Therapy involves removing the source of the ammonia from the 
intestinal tract, trapping ammonia in the colon to prevent systemic absorption, and, in 
some patients, decreasing the number of ammonia-producing bacteria in the colon. In 
patients with gastrointestinal bleeding, removing the source of ammonia involves 
eliminating blood from the gastrointestinal tract. For haemorrhage in the upper 
gastrointestinal tract, nasogastric lavage to remove blood and initiation of lactulose or 
other cathartics to speed transit through the colon are appropriate. In patients with more 
chronic encephalopathy that is not associated with bleeding, excessive ingestion of 
protein or constipation may elevate blood ammonia to levels high enough to cause 
encephalopathy. In such cases, dietary protein intake should be decreased to 
approximately 60 g per day, and lactulose or other laxatives should be prescribed to 
eliminate protein from the colon. In addition, substitution of vegetable protein for other 
protein sources appears to be of some advantage, because of a lower rate of ammonia 
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production with such foods. 52 In severe encephalopathy, dietary protein should be 
eliminated completely until the patient improves sufficiently to allow institution of a 
stable therapeutic regimen. 
The synthetic disaccharides lactulose (1, 4-galactosidofructose) and lactitol (beta-
galactosidosorbitol) have been the mainstays of medical therapy of nitrogenous hepatic 
encephalopathy for decades. Debate continues as to their efficacy, however. These agents 
target the production and absorption of ammonia and benzodiazepine receptor ligands in 
the gut. Lactulose was introduced in the 1970s as an agent for therapy of HE on the basis 
of the concept that the drug would acidify the contents of the colon, thereby favouring 
trapping of NH4+ in the lumen and prevention of absorption. In the colon, lactulose is 
metabolized by bacteria to release lactic, acetic, and other organic acids and decreases 
stool pH to approximately 5.5. In most relevant studies, treatment with lactulose is 
clinically effective in greater than 80% of patients, in whom serum ammonia levels 
decrease and the encephalopathic changes abate (including patients with subclinical 
encephalopathy revealed by psychometric testing).Treatment with lactulose is well 
tolerated, and the principal toxic effects are abdominal cramping, diarrhea, and flatulence. 
When administered orally to normal adults in amounts up to 160 g per day, lactulose 
decreases faecal ammonia production and increases faecal nitrogen excretion 
approximately four-fold, as a result of an increase in stool volume. An increase in the 
number of bowel movements to two to four soft stools per day is an important therapeutic 
goal. In comparative clinical trials, lactulose and lactitol have been equally effective, but 
a trend toward better palatability and fewer side effects with lactitol has been observed. 
Over longer periods in the outpatient setting, evidence suggests that efforts to modulate 
colonic bacterial flora to increase the proportion on non-urease producing Lactobacillus 
species can lower blood ammonia levels, with subsequent abatement of encephalopathy 
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Several antibiotics, including neomycin, ampicillin, and rifaximin, also are 
effective in lowering blood ammonia levels. 53 The effect of these antibiotics on ammonia 
is the result in large part of a decrease in the number of colonic bacteria and a 
concomitant decrease in bacterial urease and protease activity, the main enzymes 
responsible for generation of ammonia. In addition, decreasing colonic bacteria appears to 
decrease the production of benzodiazepine receptor ligands. 54 In most patients, the 
response to antibiotics is equivalent to that of lactulose, and in small series, use of 
antibiotics has been associated with improved patient compliance. Nonspecific use of 
antibiotics in the absence of an established or suspected infection raises concerns, 
however. For example, neomycin can be absorbed systemically in concentrations 
sufficient to induce ototoxicity and nephrotoxicity, particularly when the drug is given 
over long periods. Furthermore, the alterations in gut flora associated with antibiotic use 
can contribute to diarrhoea, malabsorption, and staphylococcal and other bacterial 
overgrowth syndromes. Therefore, chronic therapy with antibiotics should be reserved for 
patients who cannot tolerate oral lactulose or lactitol therapy, and neomycin should be 
avoided. 
The relative benefit of nonabsorbable disaccharides as compared with antibiotics 
for acute HE has been evaluated in a review of 22 randomized clinical trials. Although 
effective alone, lactulose and lactitol were not as effective as antibiotics, but it was 
unclear whether the difference was clinically important. 
Treatment of HE in the absence of elevated blood ammonia levels follows the 
same principles as those for nitrogenous HE, including a careful review of the patient's 
use of sedatives and analgesics. Prolonged recovery from sedatives given for endoscopy 
or other procedures is characteristic of patients with HE. Therapy to lower blood 
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ammonia levels appears to be effective in these patients, perhaps because of the effects on 
GABA-ergic transmission. 
The role of flumazenil and other benzodiazepine receptor antagonists is not yet 
defined.  In clinical trials, evidence for 55 and against a clinical benefit with these agents 
has been presented. Even when the response was favourable, the recovery was rarely 
complete and was short-lived because of the pharmacokinetic properties of the drug. A 
review of 13 trials concluded that the short-term beneficial effect was not associated with 
significant improvement in the rates of recovery and mortality. 56 Much remains to be 
learned regarding the origin, overall contribution, and therapy of increased GABAergic 
transmission in HE. At present, as suggested by Jones and others, therapy with flumazenil 
should be limited to (1) reversing the effects of exogenous benzodiazepines; (2) aiding in 
the differential diagnosis of encephalopathy; and (3) providing information about 
prognosis in HE. These indications are likely to evolve with additional clinical experience 
and the development of more selective and effective benzodiazepine receptor analogs. 
There is a long history of clinical trials involving other more experimental 
approaches to the treatment of HE. These approaches have included use of levodopa, 
branched-chain amino acids, charcoal hemoperfusion, and molecular adsorbents. 57 
Although anecdotal reports have been encouraging, none of these therapies has been 
sufficiently beneficial to lead to widespread application. 
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MATERIALS AND METHODS 
 
This cross-sectional study was carried out in the Department of Medical 
Gastroenterology, Madras Medical College, Chennai. This is the major referral 
tertiary care center available to the population of Tamilnadu, Pondicherry, and 
neighbouring states Andhra Pradesh and Karnataka. The main aim of this study was to 
non-invasively observe the cerebral hemodynamics in patients with liver cirrhosis and 
to determine the role of cerebral hemodynamics in the causation of hepatic 
encephalopathy.  The study was carried between the periods of January 2009 to 
December 2009 (12 months) 
Fifty patients with cirrhosis were included. Twenty-five with and without 
encephalopathy in each group. 
 
Inclusion criteria  
Patients with clinical diagnosis of hepatic cirrhosis with and without hepatic 
encephalopathy admitted to the department of Medical Gastroenterology, Madras Medical 
College, Chennai.  
The diagnosis of cirrhosis is based on typical clinical findings (shrunken liver, 
signs of portal hypertension like splenomegaly, ascites etc) characteristic features by 
using ultrasonography or computed tomography and supporting biochemical data.  
Clinical encephalopathy is graded based on West Haven criteria.  
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Table 2 Clinical Stages of Hepatic Encephalopathy 
 
Exclusion criteria  
1. Recent alcohol intake. 
2. Cerebrovascular disease. 
3. Cardiac disease. 
4. Peripheral vascular disease. 
5. Chronic pulmonary disease. 
Protocol  
1. All patients who met the above criteria were included in the study and got 
admitted in our department. The following were noted in each patient 
2. Age  
3. Sex 
4. Presenting complaint 
5. Precipitating factors for encephalopathy (gastrointestinal bleed, constipation, 
azotemia, infection, hypokalemia, sedatives, others) 
6. Personal history – alcohol intake (duration and quantity) 
7. Vital data – heart rate and blood pressure 
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8. A thorough physical examination was done in all the patients. Signs of chronic 
liver disease with portal hypertension like palmar erythema, spider naevi, 
gynaecomastia, fetor hepaticus, and asterixis were noted. Abdominal examnation 
was done. Encephalopathy was graded according to West Haven criteria. 
Investigations  
The following investigations were done in patients with cirrhosis (30 patients) 
1. Liver function tests  
2. Renal function tests 
3. Prothrombin time / INR 
4. Viral markers (HBsAg, Anti-HCV ) 
5. Ultrasound of the abdomen/ Computed tomography (some patients) 
6. Diagnostic upper GI endoscopy 
7. Stage of liver disease assessed based on Child-Turcotte-Pugh classification 
 
Table 3 CHILD-TURCOTTE-PUGH CLASSIFICATION 
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Measurement of cerebral hemodynamics 
After the subjects had rested for half-an-hour in supine position in a quiet room, 
the measurement of cerebral hemodynamics were carried out by the same observer by 
using a Duplex Doppler apparatus with color Doppler sonographer (Fig 3a) and a 
Transcranial Doppler probe (SIEMENS ACUSON Antares). The right middle cerebral 
artery was identified through the temporal ultrasound window with color Doppler 
ultrasonography (Fig 3b). The pulsatility index and resistive index were automatically 
calculated according to the following formulas: 
Pulsatility index = (peak systolic velocity – end-diastolic minimum velocity)/mean 
velocity; 
Resistive index = (peak systolic velocity – end-diastolic minimum velocity)/ peak 
systolic velocity. 
To minimize measurement error, each result is expressed as mean of two 
measurements. 
Statistical analysis: 
 
 All values are expressed as the mean±SD. Statistical analysis of the results was 
conducted by using analysis of variance (ANOVA), t-test and Chi-square tests. 
Correlation analysis was carried out by using univariate linear regression analysis. To 
identify independent factors predictive of transcranial Doppler parameters, multiple 
regression analysis was performed. A P<0.05 was considered statistically significant. 
Statistical analysis was performed using SPSS software version 15.0. 
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. 
Figure 3a Siemens Acuson Antares Doppler Ultrasound apparatus 
 
      
Fig 3b Photograph showing sampling volume positioned within middle cerebral artery 
and time-velocity waveform 
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Statistical analysis: 
 
 All values are expressed as the mean±SD. Statistical analysis of the results was 
conducted by using analysis of variance (ANOVA), t-test and Chi-square tests. 
Correlation analysis was carried out by using univariate linear regression analysis. To 
identify independent factors predictive of transcranial Doppler parameters, multiple 
regression analysis was performed. A P<0.05 was considered statistically significant. 
Statistical analysis was performed using SPSS software version 15.0. 
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RESULTS 
The clinical data for the subjects are shown in Table 4 
 
Table 4 
CHARACTERISTICS OF 45 PATIENTS IN THIS STUDY 
 
Variable Normal range Controls 
(n=15) 
Mean±SD  
Cirrhosis. No 
HE (n=15) 
Mean±SD 
Cirrhosis. HE. 
(n=15) 
Mean±SD 
Age (yr) - 47.40±6.36 
 
48.53±6.22 
 
48.13±6.10 
 
Gender (M/F) - 15/0 15/0 15/0 
MBP (mm Hg) - 87.67±1.67* 86.60±5.30* 82.67±5.23 
Heart rate 
(bpm) 
- 82.27±3.01 84.13±6.02 86.00±6.18 
Bilirubin 
(mg/dL) 
0.2-1.2 0.76±0.11* 1.64±1.43 3.78±4.57 
Albumin 
(g/dL) 
3.5-5.0 3.88±0.34 3.50±0.27# 3.20±0.40# 
AST (IU/L) <40 29.33±3.90* 43.07±27.98 55.07±29.97 
PT  11.1-13.1s 1.05±0.05 1.34±0.24# 1.42±0.30# 
*P<0.05 compared with HE group    #P<0.05 compared with control 
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Fig 4 Cerebral Pulsatility index in controls and patients with cirrhosis 
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Fig 5 Cerebral Resistive index in controls and patients with cirrhosis  
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 Pulsatility and resistive indices of the right middle cerebral artery in all 
subjects are shown in fig 4 and 5 and tabulated in tables 6 and 7. 
 
Table 6 
Multiple Comparisons
Dependent Variable: PI
Tukey HSD
-.13733* .02670 .000 -.2022 -.0725
-.25067* .02670 .000 -.3155 -.1858
.13733* .02670 .000 .0725 .2022
-.11333* .02670 .000 -.1782 -.0485
.25067* .02670 .000 .1858 .3155
.11333* .02670 .000 .0485 .1782
(J) Group
No HE
HE
Control
HE
Control
No HE
(I) Group
Control
No HE
HE
Mean
Difference
(I-J) Std. Error Sig. Lower Bound Upper Bound
95% Confidence Interval
The mean difference is significant at the .05 level.*. 
 
Table 7 
Multiple Comparisons
Dependent Variable: RI
Tukey HSD
-.08467* .01229 .000 -.1145 -.0548
-.12867* .01229 .000 -.1585 -.0988
.08467* .01229 .000 .0548 .1145
-.04400* .01229 .003 -.0739 -.0141
.12867* .01229 .000 .0988 .1585
.04400* .01229 .003 .0141 .0739
(J) Group
No HE
HE
Control
HE
Control
No HE
(I) Group
Control
No HE
HE
Mean
Difference
(I-J) Std. Error Sig. Lower Bound Upper Bound
95% Confidence Interval
The mean difference is significant at the .05 level.*. 
 
 
Significant differences in cerebral pulsatility and resistive indices were found 
among these three groups (ANOVA: F = 44.19, P<0.001 for pulsatility index; F = 56.60, 
P<0.001 for resistive index). The cerebral pulsatility in patients with hepatic 
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encephalopathy (HE) (1.00±0.01) was higher than those without HE (0.89±0.05) and 
controls (0.75±0.04). Similarly, the resistive index in patients with HE (0.65±0.04) was 
higher than those without HE (0.61±0.03) and controls (0.52±0.01). 
The cerebral resistive index in child C was found to be higher (0.67±0.06) 
compared to child A (0.61±0.04). Similar trend was not observed for pulsatility index. 
These cerebral hemodynamic parameters (Pulsatility and Resistive indices) were 
compared with the results of clinical laboratory tests in patients with liver cirrhosis (Table 
8). With univariate analysis the pulsatility and resistive indices were significantly 
correlated with mean blood pressure, bilirubin and albumin. Multivariate analysis showed 
that only bilirubin was significant independent predictor of cerebral pulsatility index 
(Table 9) 
 
Table 8 
Relationship of cerebral pulsatility and resistive indices with clinical laboratory test 
results in patients with liver cirrhosis 
  Pulsatility 
Index 
 Resistive 
Index 
 
 N R P R P 
Heart Rate 30 0.16 NS 0.17 NS 
Mean BP 30 -0.42 0.01 -.0.552 0.002 
Bilirubin 30 0.612 0.00 0.551 0.002 
Albumin  30 -.0.50 0.005 -0.43 0.017 
AST  30 0.13 NS 0.21 NS 
PT 30 0.44 0.013 0.26 NS 
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Table 9 
Multivariate analysis of the relationships among laboratory tests with cerebral pulsatility 
and resistive indices in patients with liver cirrhosis 
 PI   RI   
Variables Regression 
coefficient 
SE P value Regression 
coefficient 
SE P value 
MBP -.002 0.003 0.504 -.003 0.001 0.057 
BIL 0.01 0.006 0.029 0.005 0.003 0.085 
ALB -.043 0.054 0.431 -.004 0.024 0.872 
Pulsatility index, correlation coefficient (R) = 0.641, R2 = 0.410; resistive index, 
correlation coefficient (R) = 0.639, R2 = 0.408;  
 
 Fifteen of the patients with cirrhosis had clinical hepatic encephalopathy (HE; 
grade of I-III; Fig 6). The cerebral pulsatility index was higher in patients with grade II 
encephalopathy (1.02±0.11) compared with patients without HE (0.89±0.05). The 
cerebral resistive index was also higher in patients with grade II encephalopathy 
(0.66±0.04) compared with patients without encephalopathy (0.61±0.03). Similar 
observation was not seen with other grades of encephalopathy. Also, significant 
differences by ANOVA in cerebral pulsatiliity (F = 5.01, P = 0.007) and resistive indices 
(F = 4.05, P = 0.017were found among the three subgroups of HE.  
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Fig 6 
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 To find out whether the presence of hepatic encephalopathy influences the 
cerebral hemodynamics in cirrhotics patients, TCD parameters were compared between 
cirrhotic patients with and without encephalopathy with the same Child-Pugh grade (fig 
7). The cerebral pulsatility index in patients with hepatic encephalopathy (0.99±0.06) was 
higher than that in patients without HE (0.89±0.06) in the Child-Pugh grade B. similarly 
the resistive index was also higher (0.65±0.02) in those with HE compared to those 
without HE (0.61±0.02) in the Child-Pugh grade B.  
 
 
Fig 7 
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DISCUSSION 
Cerebral blood flow (CBF) is found to be reduced in patients with cirrhosis. 
Compared to healthy volunteers, intravenous injection of 133Xenon in cirrhotic patients 
revealed reduced CBF. 58 Cerebral blood flow in cortical areas is also decreased in 
patients with alcoholic cirrhosis. 59 Similar reduction in CBF was found in alcoholic and 
non- alcoholic cirrhosis patients by single photon emission computed tomography 
(SPECT) compared to controls. 60  
Guevera et al have measured the cerebral resistive index (RI) instead of CBF in 
cirrhotic patients and demonstrated that RI is higher in cirrhotics with ascites compared to 
controls. 4 Cerebral pulsatility index (PI) and resistive index (RI) are more accurate than 
cerebral blood velocity as indicators of cerebral vascular resistance. 
 In this study, both pulsatility and resistive indices of the middle cerebral 
artery were significantly higher in cirrhotic patients compared to controls. These results 
were in agreement with those of Guevera et al. Patients with Child-Pugh C had higher RI 
compared to Child-Pugh A indicating that the cerebral resistance (RI) increased with the 
severity of liver cirrhosis. Though the pulsatility and resistive indices were significantly 
correlated with mean blood pressure, bilirubin and albumin, multivariate analysis showed 
that only bilirubin was significant independent predictor of cerebral pulsatility index and 
therefore the cerebral resistance. Cerebral resistance changes in parallel with the changes 
of cerebral perfusion pressure, and maintains a constant CBF under autoregulation. 61 
Elevated cerebral vascular resistance in early cirrhosis is attributed to expanded total 
blood volume by compensated abnormal renal sodium handling of pre-ascitic stage. 62 
Similar increase in decompensated cirrhosis may be caused by an overactivation of the 
rennin-angiotensin-aldosterone system and the sympathetic nervous system secondary to 
increasing systemic arterial vasodilatation. Advanced cirrhotic patients often exhibit 
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impaired cerebral autoregulation. Larsen et al reported that the autoregulation is 
functionally lost in some cirrhotics. 63 Therefore, in the advanced cirrhotic patients with 
high cerebral resistance, systemic hypotension may result in cerebral hypoperfusion under 
impaired autoreulation.   
 To find out whether the presence of hepatic encephalopathy is related to the 
cerebral vascular resistance, we compared cerebral PI and RI in patients with and without 
encephalopathy with the same Child-Pugh grade.  The cerebral pulsatility and resistive 
indices in patients with hepatic encephalopathy was higher than that in patients without 
HE in the Child-Pugh grade B. The cerebral pulsatility and resistive indices were higher 
in patients with grade II encephalopathy compared with patients without HE. Similar 
observation was not seen with other grades of encephalopathy Almdal et al and 
Rodriguez et al 64 have also reported that CBF decreases in patients with hepatic 
encephalopathy or with subclinical hepatic encephalopathy. Hepatic encephalopathy is 
clearly related to increased cerebral vascular resistance. These findings indicate that 
cerebral vascular resistance may reflect reversible functional changes rather than 
irreversible anatomic damage. 
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CONCLUSION 
 Cerebral pulsatility and resistive indices of the middle cerebral artery are 
significantly higher in cirrhotic patients compared to controls indicating higher cerebral 
vascular resistance in cirrhotic patients. 
Patients with Child-Pugh C have higher resistive index compared to Child-Pugh A 
indicating that the cerebral resistance (RI) increases with the severity of liver cirrhosis. 
Serum bilirubin significantly correlates with cerebral pulsatility index and 
therefore the cerebral resistance. 
The cerebral pulsatility and resistive indices are higher in patients with hepatic 
encephalopathy compared to patients without encephalopathy.  
The cerebral pulsatility and resistive indices are higher in patients with grade II 
encephalopathy compared with patients without encephalopathy. Hence hepatic 
encephalopathy is clearly related to the cerebral vascular resistance and could play a role 
in its pathogenesis. 
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STUDY ON CVR USING TCD  
PROFORMA 
Name:    Age/Sex:   IP No: 
Address:       Phone No: 
Ward  
 
Presenting complaints:    Duration:                
 
 
 
Encephalopathy  :  Grade I    /     II      /    III     /       IV 
Precipitating factors  : Yes/No  Details  
1) Azotemia   :  
2) Infection   : 
3) Hypokalemia/alkalosis: 
4) Constipation  : 
5) GI bleed  : 
6) Excess dietary protein : 
7) Sedatives  : 
8) Others   : 
 
 
 
No.  
 67
 
Personal History: 
Alcohol intake  :  Yes/No  Duration:  
        Amount:         
      
Examination   : 
Vital data   : 
Heart Rate   : 
Blood pressure (mean) : 
 
Signs of CLD:  Spider nevi/ parotid enlargement/ gynecomastia/ testicular 
atrophy/ sparse axillary hair / Dupuytren contracture 
 
  
Abdomen:    Details: 
Liver  
Spleen 
Free fluid : Minimal/ Moderate/ Tense   
Tenderness: Present/ Absent 
 68
 
 
Investigations: 
TC   DC: N/L/E: 
Platelet count:   ESR: 
LFT   : 
RFT   : 
PT/INR  :  
HBsAg/Anti HCV : 
Upper GI endoscopy: 
 
USG abdomen:     CT Abdomen: 
Liver:   
Spleen: 
PV:   
Free fluid:  
CHILD CLASS: Encephalopathy/ Ascites/ Albumin/ STB/ PT: A / B / C  
 
TCD:    VALUE 1  VALUE 2  MEAN 
 
PI 
RI 
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CONSENT FORM  
Title of Project: 
Name of Researcher:  
Please tick 
to confirm 
•I confirm that I have read and understand the information provided to me 
for the above study.  
•I have had the opportunity to consider the information, ask questions and 
have had these answered satisfactorily.  
•I understand that my participation is voluntary and that I am free to withdraw at any time, without giving any reason, without my medical 
care or legal rights being affected.  

•I agree to take part in the above research study.  
 
__________________________
Name of Patient  
______________
Date 
__________________________ 
Signature 
__________________________
Name of Person taking consent  
(if different from researcher) 
______________
Date 
__________________________ 
Signature 
__________________________
Researcher 
______________
Date 
__________________________ 
Signature 
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MASTER CHART – CONTROLS 
 
 
 
S NO AGE SEX HR MBP BIL AST ALB PT PI RI 
1 43 M 80 88 0.9 30 3.5 1.1 0.64 0.56
2 45 M 78 86 0.8 32 3.5 1.0 0.76 0.53
3 42 M 82 90 0.8 28 4.0 1.0 0.74 0.52
4 40 M 84 88 0.7 26 4.2 1.1 0.76 0.53
5 60 M 80 90 0.9 28 4.4 1.0 0.77 0.51
6 53 M 86 86 0.9 30 4.5 1.1 0.78 0.50
7 45 M 84 86 0.7 32 4.0 1.0 0.78 0.53
8 43 M 82 87 0.6 34 3.8 1.1 0.79 0.55
9 45 M 80 88 0.7 28 3.6 1.1 0.80 0.54
10 50 M 88 86 0.6 30 3.5 1.0 0.79 0.55
11 57 M 82 86 0.6 34 4.2 1.1 0.78 0.52
12 43 M 84 90 0.7 36 4.0 1.0 0.76 0.53
13 50 M 86 88 0.9 22 3.8 1.1 0.74 0.52
14 40 M 78 90 0.8 24 3.8 1.0 0.71 0.51
15 55 M 80 86 0.8 26 3.4 1.1 0.77 0.53
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MASTER CHART 
CIRRHOSIS WITHOUT HEPATIC ENCEPHALOPATHY 
 
 
 
S 
no 
age sex Alcohol HR MBP BIL AST alb PT Cr Child PI RI 
1 44 M N 76 83 4.7 45 3.2 2.12 0.6 B 1.01 0.6 
2 62 M Y 86 94 1.4 88 3.4 1.4 0.8 A 0.91 0.62 
3 59 M N 88 83 0.7 30 3.4 1.2 0.8 B 0.98 0.68 
4 47 M Y 86 80 0.9 46 3.2 1.1 0.8 B 0.93 0.63 
5 45 M N 68 83 1.5 28 3.6 1.2 0.9 A 0.98 0.62 
6 45 M N 88 90 0.9 25 3.8 1.2 1.0 A 0.93 0.65 
7 42 M Y 88 83 5.1 124 3.5 1.5 0.9 B 0.82 0.63 
8 45 M Y 86 90 0.9 22 4.2 1.5 1.1 A 0.82 0.60 
9 50 M Y 88 90 3.0 50 3.2 1.3 0.9 B 0.89 0.62 
10 48 M Y 80 93 0.8 22 3.4 1.3 0.9 B 0.85 0.58 
11 50 M Y 90 95 0.9 21 3.5 1.4 0.8 A 0.88 0.51 
12 56 M Y 78 79 0.9 32 3.8 1.3 0.7 A 0.87 0.63 
13 45 M Y 86 90 0.9 42 3.3 1.2 1.0 B 0.84 0.60 
14 50 M Y 88 84 0.9 36 3.5 1.2 0.9 B 0.86 0.61 
15 40 M Y 86 82 1.1 35 3.6 1.2 0.9 A 0.86 0.62 
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MASTER CHART 
CIRRHOSIS WITH HEPATIC ENCEPHALOPATHY 
 
 
 
 
S 
no 
age sex grade HR MB
P 
BIL AS
T 
alb PT Cr Child PI RI 
1 45 M 2 74 92 0.8 22 4.2 1.39 2.2 A 0.99 0.64 
2 45 M 2 88 80 5.0 47 2.9 1.3 1.4 C 0.88 0.64 
3 40 M 1 88 80 1.2 38 3.2 1.33 1.1 B 0.88 0.62 
4 40 M 2 100 73 17.4 71 2.4 2.21 1.3 C 1.33 0.78 
5 60 M 3 92 83 0.8 22 3.2 1.34 1.3 B 0.92 0.62 
6 55 M 2 80 84 8.9 80 3.3 1.8 0.7 C 0.98 0.68 
7 47 M 2 88 80 7.2 132 3.1 1.4 1.0 C 0.98 0.62 
8 45 M 2 78 76 0.9 46 3.2 1.4 0.8 B 1.01 0.69 
9 47 M 3 88 80 5.3 98 2.8 1.9 1.3 C 0.99 0.64 
10 48 M 2 86 90 1.1 36 3.1 1.2 0.7 B 1.03 0.68 
11 58 M 2 80 86 0.9 46 3.2 1.1 0.8 B 1.03 0.69 
12 46 M 1 86 84 0.9 26 3.8 1.2 1.0 B 1.05 0.64 
13 52 M 2 86 82 2.6 50 3.2 1.3 0.9 B 1.06 0.64 
14 42 M 2 88 80 2.6 56 3.1 1.2 0.9 B 1.01 0.65 
15 52 M 2 88 90 1.2 56 3.4 1.3 0.8 B 0.99 0.63 
 
 
 
 
